{"id":"NCT04199104","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","officialTitle":"A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-05","primaryCompletion":"2023-05-30","completion":"2025-03-31","firstPosted":"2019-12-13","resultsPosted":"2024-07-16","lastUpdate":"2025-04-23"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Lenvatinib","otherNames":["E7080","MK-7902","LENVIMA®"]},{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","Keytruda®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pembrolizumab with Lenvatinib","type":"EXPERIMENTAL"},{"label":"Pembrolizumab with Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.\n\nHypotheses include:\n\n* Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).\n* Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR.\n* Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to overall survival (OS).","primaryOutcome":{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to ~ 37 months","effectByArm":[{"arm":"Pembrolizumab + Lenvatinib","deltaMin":46.9,"sd":null},{"arm":"Pembrolizumab + Placebo","deltaMin":27.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0000019"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":26},"locations":{"siteCount":152,"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Hungary","Italy","Japan","Mexico","Peru","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["33300372"],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":152,"n":254},"commonTop":["Hypothyroidism","Hypertension","Fatigue","Anaemia","Diarrhoea"]}}